Breaking News Instant updates and real-time market news.

AKTX

Akari Therapeutics

$6.03

0.3 (5.24%)

07:09
10/11/17
10/11
07:09
10/11/17
07:09

Akari Therapeutics completes enrollment in COBALT Phase II PNH trial of Coversin

Akari Therapeutics announces that three additional patients have been enrolled in the ongoing Phase II COBALT clinical trial of Coversin in patients with paroxysmal nocturnal hemoglobinuria, or PNH. COBALT, the Phase II 90-day, open label single arm clinical trial, has enrolled a total of eight patients, four of whom have completed the trial and were reported on at the European Hematology Association conference in June 2017. These four patients have all moved into Akari's long-term safety study, CONSERVE. One of the initial five patients enrolled in the COBALT trial, with a suspected co-morbidity unrelated to the treatment, was withdrawn from the study on day 43. Three new patients were enrolled pursuant to an amended protocol based on a revised dosing regimen which included changing the maintenance phase from a single dose of 30mg every 24 hours to a single dose of 45mg every 24 hours. The three newly enrolled patients on the revised dosing regimen have now completed approximately 8, 3 and 2 weeks, respectively. The primary endpoint in this clinical trial is reduction in serum LDH, or lactate dehydrogenase; an indication of hemolysis, to less than or equal to 1.8 times the ULN, or upper limit of normal, for the investigator's reference laboratory or 500 I U/L, whichever is the lower from day 1 to day 28. The first of the three patients had a LDH value of 1.5 times the ULN at day 28. The other two patients have not yet reached the primary endpoint measurement date. To date, there have been no drug-related serious adverse events. The data reported is taken from the current electronic case report forms. Akari plans to provide an update on all PNH patients currently enrolled at the American Society of Hematology Annual Meeting to be held December 9-12, 2017. Akari plans to advance Coversin towards Phase III clinical trials beginning with CAPSTONE in Q1 2018, a Phase III clinical trial of Coversin in naive PNH patients.

AKTX Akari Therapeutics
$6.03

0.3 (5.24%)

05/31/17
CHDN
05/31/17
UPGRADE
CHDN
Neutral
Akari Therapeutics upgraded to Neutral from Sell at Chardan
05/31/17
05/31/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Donaldson (DCI) upgraded to Buy from Hold at Jefferies with analyst Laurence Alexander saying he sees "increasing evidence" the company's end-markets are exiting the multi-year trough and believes operating leverage should translate into above-average compound growth over the next few years. He recommends building positions in the stock during the second half of 2017. 2. VMware (VMW) upgraded to Outperform from Neutral at Baird with analyst Jason Noland citing the company's strategic shift to partner with firms rather than compete with the public cloud. 3. Akari Therapeutics (AKTX) upgraded to Neutral from Sell at Chardan. 4. Vale (VALE) upgraded to Buy from Hold at HSBC with analyst Jonathan Brandt saying the recent decline in iron ore prices has mitigated risk, and the focus should now shift to the company's "strong" free cash flow generation and 6% dividend yield. 5. Potbelly (PBPB) upgraded to Buy from Hold at Maxim with analyst Stephen Anderson citing news that Chief Executive Officer Aylwin Lewis is resigning, as he believes new management could reinvigorate performance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/27/17
ADAM
06/27/17
NO CHANGE
Target $15
ADAM
Buy
Akari Therapeutics price target lowered to $15 from $33 at Canaccord
Canaccord analyst Arinda Lee lowered her price target on Akari Therapeutics to $15 from $33 following its Coversin data presentation at the EHA meeting. Lee said Coversin's efficacy is competitive, as the data indicated meaningful benefit in PNH without generating neutralizing antibodies or serious adverse events, but its pushed out timelines for launch and the lowered probability of success due to aggressive competition caused her to lower her targets. Lee reiterated her Buy rating on Akari Therapeutics shares.
09/22/17
WBLR
09/22/17
UPGRADE
WBLR
Outperform
Akari Therapeutics upgraded to Outperform from Market Perform at William Blair
William Blair analyst Tim Lugo upgraded Akari Therapeutics to Outperform saying coversin is progressing towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria with an achievable endpoint.

TODAY'S FREE FLY STORIES

YOGA

YogaWorks

$2.86

-0.04 (-1.38%)

07:07
10/19/17
10/19
07:07
10/19/17
07:07
Hot Stocks
YogaWorks acquires seven Houston studios »

YogaWorks announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QURE

uniQure

$9.47

-2.2 (-18.85%)

07:07
10/19/17
10/19
07:07
10/19/17
07:07
Hot Stocks
uniQure acquires patent family providing protection of FIX-Padua »

uniQure N.V. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEVA

CEVA

$45.15

-0.25 (-0.55%)

07:07
10/19/17
10/19
07:07
10/19/17
07:07
Hot Stocks
CEVA and Cyberon partner for voice activation solution for smartphones »

CEVA and Cyberon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

RCI

Rogers Communications

$53.75

-0.23 (-0.43%)

07:07
10/19/17
10/19
07:07
10/19/17
07:07
Hot Stocks
Breaking Hot Stocks news story on Rogers Communications »

Rogers Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SBGI

Sinclair Broadcast

$30.35

0.3 (1.00%)

, TRCO

Tribune Media

07:06
10/19/17
10/19
07:06
10/19/17
07:06
Periodicals
FCC extends comment period for Sinclair-Tribune deal, Reuters reports »

The Federal…

SBGI

Sinclair Broadcast

$30.35

0.3 (1.00%)

TRCO

Tribune Media

DISH

Dish

$49.71

0.86 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

RCI

Rogers Communications

$53.75

-0.23 (-0.43%)

07:06
10/19/17
10/19
07:06
10/19/17
07:06
Earnings
Rogers Communications backs FY17 revenue growth view 3%-5% 

Consensus $11.34B.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

NAK

Northern Dynasty

$2.09

0.1 (5.03%)

07:06
10/19/17
10/19
07:06
10/19/17
07:06
Initiation
Northern Dynasty initiated  »

Northern Dynasty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESTE

Earthstone Energy

$10.54

-0.15 (-1.40%)

07:05
10/19/17
10/19
07:05
10/19/17
07:05
Syndicate
Earthstone Energy 4.5M share Spot Secondary priced at $9.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 16

    May

  • 19

    Oct

RCI

Rogers Communications

$53.75

-0.23 (-0.43%)

07:05
10/19/17
10/19
07:05
10/19/17
07:05
Hot Stocks
Rogers Communications raises FY17 adj operating profit growth view to 5%-6% »

With plans to invest the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

PM

Philip Morris

$112.51

-0.14 (-0.12%)

07:05
10/19/17
10/19
07:05
10/19/17
07:05
Hot Stocks
Philip Morris CEO says Q3 results 'very strong' »

"As expected, our…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

BX

Blackstone

$33.49

0.27 (0.81%)

07:05
10/19/17
10/19
07:05
10/19/17
07:05
Earnings
Blackstone reports Q3 ENI 69c, consensus 54c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 07

    Nov

ABCB

Ameris Bancorp

$49.45

0.3 (0.61%)

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Earnings
Ameris Bancorp reports Q3 adjusted EPS 63c, consensus 65c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 15

    Nov

  • 28

    Nov

V

Visa

$107.80

0.26 (0.24%)

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Hot Stocks
Visa announces security platform Visa ID Intelligence »

Visa announced Visa ID…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Nov

PM

Philip Morris

$112.51

-0.14 (-0.12%)

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Earnings
Philip Morris revises FY17 reported EPS view to $4.75-$4.80, consensus $4.84 »

PMI revises its 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SPX

S&P 500

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Hot Stocks
Trump thinks Republicans have votes for budget approval »

President Trump just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$53.75

-0.23 (-0.43%)

07:03
10/19/17
10/19
07:03
10/19/17
07:03
Earnings
Rogers Communications reports Q3 EPS C$1.01, consensus C$0.80 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

PM

Philip Morris

$112.51

-0.14 (-0.12%)

07:02
10/19/17
10/19
07:02
10/19/17
07:02
Earnings
Philip Morris reports Q3 adjusted EPS $1.27, consensus $1.38 »

Reports Q3 revenues,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ERIC

Ericsson

$5.98

0.08 (1.36%)

07:02
10/19/17
10/19
07:02
10/19/17
07:02
Downgrade
Ericsson rating change  »

Ericsson downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$130.02

1.37 (1.06%)

07:01
10/19/17
10/19
07:01
10/19/17
07:01
Hot Stocks
Travelers reports Q3 combined ratio of 103.2% »

Including 10.7 points of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 13

    Nov

USO

United States Oil Fund

$10.48

-0.01 (-0.10%)

07:01
10/19/17
10/19
07:01
10/19/17
07:01
Technical Analysis
United States Oil Fund: Pivot points, pivot low edged »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$33.35

-0.32 (-0.95%)

07:00
10/19/17
10/19
07:00
10/19/17
07:00
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$26.40

0.3 (1.15%)

06:59
10/19/17
10/19
06:59
10/19/17
06:59
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$130.02

1.37 (1.06%)

06:59
10/19/17
10/19
06:59
10/19/17
06:59
Hot Stocks
Breaking Hot Stocks news story on Travelers »

Travelers reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 13

    Nov

UGAZ

VelocityShares 3x Long Natural Gas ETN

$10.23

-0.17 (-1.63%)

06:58
10/19/17
10/19
06:58
10/19/17
06:58
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$130.02

1.37 (1.06%)

06:58
10/19/17
10/19
06:58
10/19/17
06:58
Hot Stocks
Travelers reports Q3 book value per share $86.73 »

Reports Q3 adjusted book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.